Comparative Effectiveness Research in Veterans With PTSD



Status:Active, not recruiting
Conditions:Psychiatric, Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - Any
Updated:3/8/2019
Start Date:October 31, 2014
End Date:April 30, 2019

Use our guide to learn which trials are right for you!

CSP #591 - CERV-PTSD: Comparative Effectiveness Research in Veterans With PTSD

VA Cooperative Study CSP #591 is designed to compare the effectiveness of two types of
psychotherapy, Prolonged Exposure and Cognitive Processing Therapy, for treating
posttraumatic stress disorder (PTSD) in male and female Veterans. Despite solid evidence that
both treatments are effective in Veterans and non-Veterans, there is a lack of evidence about
the effectiveness of these treatments compared with one another.

The sample will include 900 male and female Veterans with PTSD due to any traumatic military
event. Veterans who are eligible and agree to participate in the study will be randomly
assigned (by chance) to receive Prolonged Exposure or Cognitive Processing Therapy. The
standard "dose" of treatment is 12 weekly sessions but Veterans who improve more rapidly may
finish in fewer sessions and Veterans who improve more slowly may have additional sessions.
The primary outcome is improvement in PTSD symptoms after treatment. The outcome will be
measured at regular follow-up visits that will occur at the middle and at the end of
treatment and then 3 and 6 months later. The investigators will measure other outcomes,
including additional mental health problems, functioning, quality of life, and use of
treatments for mental and physical problems. The investigators also will measure Veterans'
treatment preference and examine whether Veterans who get the treatment they prefer do better
than Veterans who get the less-preferred treatment.

As a large multi-site trial with men and women, CSP #591 is designed to provide conclusive
information about whether one treatment is better than the other, overall and for different
types of patients-for example, men vs. women, combat Veterans vs. Veterans who experienced
military sexual trauma, and older vs. younger Veterans. Regardless of the outcome, patients
will have more information to help them make an informed decisions about which treatment to
choose and VA will have stronger evidence to help make care Veteran-centered.

VA Cooperative Study CSP #591 is designed to compare the effectiveness of Prolonged Exposure
and Cognitive Processing Therapy for treating posttraumatic stress disorder (PTSD) in male
and female Veterans. PTSD is a serious and prevalent condition in Veterans, affecting just
under 9% of VA patients in FY11. Since 2005, the number of VA patients with PTSD has
increased 14.8% annually, due not only to new Veterans but also to increased numbers of
Vietnam Veterans who are seeking care. In FY11, PTSD was the 3rd most common
service-connected disability in VA.

Despite solid evidence that Prolonged Exposure and Cognitive Processing Therapy are effective
treatments for PTSD in Veterans and non-Veterans, there is insufficient evidence about the
effectiveness of these treatments relative to one another. The only study to compare the
treatments, a single-site trial in non-Veteran female rape survivors, failed to find a
difference, but the study was not adequately powered to compare two such effective
treatments. Other data are similarly inconclusive. CSP #591 would break new ground as the
first large-scale comparative effectiveness trial of treatment for PTSD and the first study
to provide definitive information about how effective treatments for PTSD compare with one
another.

The study will be a prospective randomized clinical trial with blinded assessment. The
population will be male and female Veterans with PTSD due to any traumatic military event.
Patients who are eligible and agree to participate in the study will be randomly assigned in
a 1:1 ratio to receive Prolonged Exposure or Cognitive Processing Therapy. The investigators
propose to administer 12 weekly sessions of each treatment as a standard "dose" but to allow
participants who improve more rapidly to finish in 10 or 11 sessions and participants who
have not attained adequate improvement by session 12 to have up to 2 additional sessions.

The primary outcome is improvement in PTSD symptom severity as measured by change on the
Clinician-Administered PTSD Scale after treatment. The outcome measure will be determined
from regular follow-up visits of the patients, which will occur at the middle and at the end
of treatment and then 3 and 6 months later. Secondary outcomes include other measures of
PTSD, comorbid mental health problems, functioning, quality of life, and service utilization.
The investigators also will measure participants' treatment preference and examine whether
concordance between preference and allocation is associated with increased treatment
effectiveness.

In order to detect a standardized mean difference in improvement in PTSD symptom severity of
d = .25, a sample size of 900 randomized patients provides 90% power to detect a difference
between arms using the linear mixed effects model with a two-sided = .05. Given the lack of
conclusive findings to predict which treatment is better, the investigators propose to test a
nondirectional hypothesis. Assuming 2.5 years of accrual and an enrollment of 26 participants
per year at each site, the investigators would need 14.1 sites to enroll a total of 64
participants per site. The investigators propose to recruit 17 sites to guard against the
possibility that some sites will not enroll the required number of participants.

VA has a vested interest in understanding the relative effectiveness of Prolonged Exposure
and Cognitive Processing Therapy. Both treatments are recommended at the highest level in the
VA/DoD PTSD Practice Guideline. VA is required to make these treatments available to Veterans
seeking PTSD care. The treatments are being disseminated nationally across the VA system in
order to enhance the availability of evidence-based treatments to Veterans with PTSD. VA also
has developed a national PTSD Mentoring Program for PTSD Program Administrators to help them
manage their clinics to permit the delivery of these treatments. Every facility has an
evidence-based therapy coordinator as well to facilitate training in evidence-based
psychotherapy.

As a large multi-site trial with men and women, CSP #591 would provide definitive information
about the comparative effectiveness of Prolonged Exposure and Cognitive Processing Therapy
and maximize the study's impact on the field. Because the treatments are based on differing
theories about the development of PTSD, a demonstration that one treatment is superior to the
other would further scientific exploration by challenging theoretical accounts of etiology
and treatment. Regardless of which treatment is better, patients would have more information
to help them make an informed decision about which treatment to choose and VA would have
stronger evidence to help make care Veteran-centered.

Inclusion Criteria:

Current PTSD and symptom severity of 25 or higher on the Clinician- Administered PTSD Scale
(Weathers et al., 2013); agreement to not receive psychotherapy for PTSD during study
treatment and allow digital recording of phone interviews and therapy; regular access to a
telephone (or agreement to come to the VA for centrally conducted telephone interviews for
participant who do not have telephone access). Medication for PTSD and other mental or
physical conditions, psychotherapy for other problems, brief visits with an existing
therapist, and self-help groups will be allowed.

Exclusion Criteria:

- substance dependence not in remission for at least 1 month;

- current psychotic symptoms and mania (including manic phase of bipolar disorder);

- significant current suicidal or homicidal ideation that includes a specific plan;

- or moderate to severe cognitive impairment defined as 1 SD below age-graded norms on
the Montreal Cognitive Assessment.
We found this trial at
18
sites
Seattle, Washington 98108
Phone: 253-583-1774
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Albuquerque, New Mexico 87108
Phone: 505-265-1711
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Phone: 513-861-3100
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44106
Phone: 216-791-3800
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Decatur, Georgia 30033
Phone: 404-321-6111
?
mi
from
Decatur, GA
Click here to add this to my saved trials
Durham, North Carolina 27705
Phone: 919-286-0411
?
mi
from
Durham, NC
Click here to add this to my saved trials
Hines, Illinois 60141
Phone: 708-202-8387
?
mi
from
Hines, IL
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 713-794-7453
?
mi
from
Houston, TX
Click here to add this to my saved trials
Long Beach, California 90822
Phone: 562-826-8000
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Madison, Wisconsin 53705
Phone: 608-256-1901
?
mi
from
Madison, WI
Click here to add this to my saved trials
Minneapolis, Minnesota 55417
Phone: 612-467-5093
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Phone: 504-571-8294
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Palo Alto, California 94304
Phone: 650-493-5000
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Phoenix, Arizona 85012
Phone: 602-277-5551
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Salt Lake City, Utah 84148
Phone: 801-582-1565
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Francisco, California 94121
Phone: 415-221-4810
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Tuscaloosa, Alabama 35404
Phone: 205-554-2000
?
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
White River Junction, Vermont 05009
Phone: 802-296-5132
?
mi
from
White River Junction, VT
Click here to add this to my saved trials